IAVI Report

After more than three decades at the U.S. Food and Drug Administration, Gruber is continuing her legacy of changing the way vaccines are licensed and distributed.

Improving vaccine access topped the agenda at a major public health gathering in Berlin, where pandemic preparedness loomed large.

Exploring potential synergies between B- and T-cell HIV vaccine strategies is a priority for the field given results from recent trials.

Brittany Hartwell and her lab are exploring new ways to transport vaccine antigens across mucosal barriers to trigger more protective immune responses against many pathogens, including HIV.

COVID-19 illustrated once again the importance of localized epidemiological data, monitoring, and analysis.

Two new books illustrate why reflection and preparation are both essential to ensure a quicker and more equitable response to the next pandemic.

A view from Zambia on the shifting landscape of HIV vaccine research and the enduring optimism that characterizes one researcher’s drive.

Work is underway but obstacles to vaccine procurement and delivery for the next pandemic loom large.

After decades of research, structure-based design efforts are yielding effective vaccines against respiratory syncytial virus. Jason McLellan explains the breakthroughs that paved the way.

More and more people living with HIV are over 50 years old, raising new questions about efforts to slow the aging process in a population of individuals on antiretroviral therapy.

Hundreds of next-generation COVID-19 vaccines are being explored, including many that are delivered mucosally to try to prevent infection or block transmission.

After more than 50 years, Anthony Fauci leaves behind an unparalleled legacy of championing science, particularly HIV/AIDS treatment, prevention, and cure efforts.